*** Meet us at World ADC Summit 2019 – London – 5-6th March***
  • LinkedIn
  • English English English en
McSAF
  • About us
  • Team
  • Science
  • Product pipeline
  • Contact
  • Search
  • Menu Menu

Science

  • Home/
  • Science/

We believe personnalized medicine and targeted therapies are amazing therapeutic alternatives for many patients.

Our work focus on bringing chemical innovation to antibody-drug conjugates, a sub-class of targeted therapies, in order to ensure optimal characteristics and efficacies.

To date, McSAF have developped McSAF Inside® cysteins rebridging technology platforms that can be used to produce three typologies of ADCs:

  • DAR 4, i.e. 4 drugs per antibody
  • DAR 2, i.e. 2 drugs per antibody
  • DAR 1, i.e. 1 drug per antibody
  • Homogeneity

  • Site-specificity

  • Native proteins

  • Reproducibility

McSAF Inside®, a versatile technology

McSAF Inside® results

DAR 4

Results obtained on ADC with MMAE conventional linker (native mass spectrometry analysis)

DAR 2

Results obtained on ADC with MMAE click linker (native mass spectrometry analysis)

DAR 1

Results obtained on ADC with MMAE click linker (mass spectrometry analysis)

BIBLIOGRAPHY

> Novel antibody-drug conjugates and the use of same in therapy Joubert, N ; Viaud-Massuard, MC ; Respaud, R. Patent. WO2015004400A1.

Patent delivered in US / CN / JP

> Conjugués anticorps-médicament et leur utilisation en thérapie Juen, L ; Baltus, CB Patent. WO2020234541.

> Impact of Maleimide Disubstitution on Chemical and Biological Characteristics of HER2 Antibody-Drug Conjugates Feuillâtre O. et al., ACS Omega, 2020, 5, 1557-1565

Scroll to top
Nous utilisons des cookies pour vous garantir la meilleure expérience sur notre site. Si vous continuez à utiliser ce dernier, nous considérerons que vous acceptez l'utilisation des cookies.Ok